Ind-Swift Laboratories Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a standalone revenue of 17,270.06 Lakhs for the quarter ended March 31, 2026, compared to 15,317.14 Lakhs in the previous quarter and 14,951.76 Lakhs in the corresponding quarter of the previous year. The standalone net profit after tax for the quarter ended March 31, 2026, was 1,493.86 Lakhs, compared to 1,074.18 Lakhs in the previous quarter and 21,808.84 Lakhs in the corresponding quarter of the previous year.

Ind-Swift Laboratories Limited is a pharmaceutical company engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished dosages. The company operates manufacturing facilities in Punjab and Jammu & Kashmir. Recent corporate developments include the re-appointment of M/s. V. Kumar & Associates as Cost Auditors for the financial year 2026-27. During the year, the company issued 1,80,93,000 equity shares through the conversion of share warrants and under the Employee Stock Option Plan 2014. Additionally, the company is in the process of transferring the land and building of its Unit-IV in Baddi, having already received 1,710 Lakhs of the consideration.